202 related articles for article (PubMed ID: 10389917)
21. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
22. Effect of calcitriol replacement on serum calcitonin and parathyroid hormone levels in CAPD patients.
Quesada JM; Rodriguez M; Calderon de la Barca JM; Alvarez-Lara A; Martín-Malo A; Mateo A; Martinez ME; Aljama P
Nephrol Dial Transplant; 1995; 10(1):70-4. PubMed ID: 7724033
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
Sun W; Stevenson JP; Gallo JM; Redlinger M; Haller D; Algazy K; Giantonio B; Alila H; O'Dwyer PJ
Clin Cancer Res; 2002 Oct; 8(10):3100-4. PubMed ID: 12374677
[TBL] [Abstract][Full Text] [Related]
24. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
26. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.
Muindi JR; Potter DM; Peng Y; Johnson CS; Trump DL
Cancer Chemother Pharmacol; 2005 Nov; 56(5):492-6. PubMed ID: 15918041
[TBL] [Abstract][Full Text] [Related]
29. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
31. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
[TBL] [Abstract][Full Text] [Related]
34. Calcitriol in the treatment of prostate cancer.
Beer TM; Myrthue A
Anticancer Res; 2006; 26(4A):2647-51. PubMed ID: 16886675
[TBL] [Abstract][Full Text] [Related]
35. Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model.
Wietrzyk J; Nevozhay D; Milczarek M; Filip B; Kutner A
Cancer Chemother Pharmacol; 2008 Oct; 62(5):787-97. PubMed ID: 18188568
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of tumor hypercalcemia with clodronate. Effect on parathormone and calcitriol].
Scharla SH; Minne HW; Sattar P; Mende U; Blind E; Schmidt-Gayk H; Wüster C; Ho T; Ziegler R
Dtsch Med Wochenschr; 1987 Jul; 112(28-29):1121-5. PubMed ID: 2956079
[TBL] [Abstract][Full Text] [Related]
37. Duodenal active calcium transport in female rats increases with serum calcitriol concentrations, but reaches a plateau far below maximal calcitriol levels.
Boass A; Toverud SU
J Bone Miner Res; 1996 Nov; 11(11):1640-5. PubMed ID: 8915771
[TBL] [Abstract][Full Text] [Related]
38. Single-dose oral calcitriol and changes of plasma 1,84iPTH in uremic children.
Klaus G; Schmidt-Gayk H; Roth HJ; Ritz E; Mehls O
Adv Perit Dial; 1994; 10():261-6. PubMed ID: 7999841
[TBL] [Abstract][Full Text] [Related]
39. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
Muindi JR; Johnson CS; Trump DL; Christy R; Engler KL; Fakih MG
Cancer Chemother Pharmacol; 2009 Dec; 65(1):33-40. PubMed ID: 19396601
[TBL] [Abstract][Full Text] [Related]
40. Calcitriol corrects deficient calcitonin secretion in the vitamin D-deficient elderly.
Quesada JM; Mateo A; Jans I; Rodriguez M; Bouillon R
J Bone Miner Res; 1994 Jan; 9(1):53-7. PubMed ID: 8154309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
